leadf
logo-loader
viewBetterLife Pharma Inc
(
CSE:BETROTCQB:BETRF
)

BetterLife Pharma reveals finalized rebranding by launching its new website

BetterLife Pharma Inc. (OTCQB:BETRD) (CSE:BETR) CEO Ahmad Doroudian tells Proactive the firm has finalized its rebranding exercise for its wholly-owned subsidiary, BLife Therapeutics, which has been publicly formalized through the launching of its new website.

Doroudian says the company’s name and branding is now more consistent with its intent to become a major player within the biotechnology space. The new website, http://www.blifetherapeutics.com, provides visitors with an overview of the company’s treatment development pipeline, including information on the trial Phases for each of the treatments.

Quick facts: BetterLife Pharma Inc

Follow
CSE:BETR

Price: 0.28 CAD

Market Cap: $23.75 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

BetterLife Pharma’s Interferon alpha-2b Covid-19 trial in Chile enrolls...

BetterLife Pharma CEO Ahmad Doroudian joined Steve Darling from Proactive to share news their wholly owned subsidiary, Altum Pharmaceuticals Inc. and Pontificia Universidad Católica de Chile have enrolled the first patient in the Phase 1 portion of Phase 1-2 randomized placebo-controlled study...

2 days, 2 hours ago

2 min read